Filtered By:
Vaccination: Measles Vaccine
Countries: India Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 91 results found since Jan 2013.
Immunogenicity and safety of Mebella ™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study
CONCLUSION: It was concluded from the study results that the test vaccine, Mebella™, was immunogenic and well tolerated and was non-inferior to the comparator vaccine, MR-VAC®, when administered to healthy subjects of 9 months to 49 years of age. Clinical Trial Registry of India Identifier: CTRI/2020/07/026930.PMID:37659893 | DOI:10.1016/j.vaccine.2023.08.065
Source: Vaccine - September 2, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Rahul Jahagirdar Kheya Ghosh Uttam S Srikanth Bhatt S Prashanth Vasudev Rajapantula M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research
Stories to Take the Edge Off Pain During Immunization for Preschoolers: A Randomized Controlled Trial
CONCLUSIONS AND RELEVANCE: A pictorial story is a simple and cost-effective intervention to reduce pain perception among children. What This Article Adds: Pictorial stories may be a feasible, simple, and cost-effective intervention to reduce pain perception during immunization.PMID:37326569 | DOI:10.5014/ajot.2023.050086
Source: The American Journal of Occupational Therapy - June 16, 2023 Category: Occupational Health Authors: Addlin Sarah Jerome Dany Praveen Raj Rajeev Zachariah Kompithra Leni Grace Mathew Suja Angelin Hima B John Source Type: research
Two-dose measles-rubella vaccine schedule for measles-rubella elimination
Indian J Med Res. 2023 Apr;157(4):268-270. doi: 10.4103/ijmr.ijmr_79_23.NO ABSTRACTPMID:37282389 | DOI:10.4103/ijmr.ijmr_79_23
Source: The Indian Journal of Medical Research - June 7, 2023 Category: Biomedical Science Authors: T Jacob John Source Type: research
